{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:39:26Z","timestamp":1791333566619,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA091956"],"award-info":[{"award-number":["CA091956"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.mayocp.2011.09.009","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T03:29:55Z","timestamp":1331004595000},"page":"240-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Germline Predictors of Androgen Deprivation Therapy Response in Advanced Prostate Cancer"],"prefix":"10.1016","volume":"87","author":[{"given":"Manish","family":"Kohli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun M.","family":"Riska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"High S.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak M.","family":"Sahasrabudhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocp.2011.09.009_bib1","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.009_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial","volume":"79","year":"1997","journal-title":"Br J Urol"},{"issue":"7","key":"10.1016\/j.mayocp.2011.09.009_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.009_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000019546","article-title":"EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center","volume":"33","author":"Denis","year":"1998","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.mayocp.2011.09.009_bib5","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"issue":"9214","key":"10.1016\/j.mayocp.2011.09.009_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2011.09.009_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.mayocp.2011.09.009_bib8","series-title":"SEER Cancer Statistics Review, 1975-2007","author":"Altekruse","year":"2010"},{"issue":"6","key":"10.1016\/j.mayocp.2011.09.009_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.2007.13.6804","article-title":"Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer","volume":"26","author":"Ross","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2011.09.009_bib10","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1055-9965.EPI-10-0216","article-title":"Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy","volume":"19","author":"Sun","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.mayocp.2011.09.009_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1464-410X.2008.07629.x","article-title":"A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer","volume":"102","author":"Sharifi","year":"2008","journal-title":"BJU Int"},{"issue":"18","key":"10.1016\/j.mayocp.2011.09.009_bib12","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.2010.31.2405","article-title":"SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer","volume":"29","author":"Yang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2011.09.009_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000134780","article-title":"Clinical implications of androgen synthesis via 5alpha-reduced precursors","volume":"13","author":"Ghayee","year":"2008","journal-title":"Endocr Dev"},{"issue":"9","key":"10.1016\/j.mayocp.2011.09.009_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tem.2004.09.004","article-title":"The backdoor pathway to dihydrotestosterone","volume":"15","author":"Auchus","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.mayocp.2011.09.009_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2105-12-129","article-title":"SNPPicker: high quality tag SNP selection across multiple populations","volume":"12","author":"Sicotte","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"10.1016\/j.mayocp.2011.09.009_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/gepi.20219","article-title":"Testing association between disease and multiple SNPs in a candidate gene","volume":"31","author":"Gauderman","year":"2007","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.mayocp.2011.09.009_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc B"},{"issue":"7","key":"10.1016\/j.mayocp.2011.09.009_bib18","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.009_bib19","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.009_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.urology.2004.03.032","article-title":"Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study","volume":"64","author":"Sato","year":"2004","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.009_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.mayocp.2011.09.009_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000067996","article-title":"PSA decline is an independent prognostic marker in hormonally treated prostate cancer","volume":"36","author":"Palmberg","year":"1999","journal-title":"Eur Urol"},{"issue":"5928","key":"10.1016\/j.mayocp.2011.09.009_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.mayocp.2011.09.009_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1-2","key":"10.1016\/j.mayocp.2011.09.009_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","article-title":"CYP17 inhibitors for prostate cancer therapy","volume":"125","author":"Vasaitis","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.009_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4065\/mcp.2009.0442","article-title":"New developments in the medical management of prostate cancer","volume":"85","author":"Kohli","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2011.09.009_bib27","first-page":"313","article-title":"Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review","volume":"29","author":"Bugano","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2011.09.009_bib28","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1158\/0008-5472.CAN-08-0043","article-title":"Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms","volume":"68","author":"Ji","year":"2008","journal-title":"Cancer Res"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612001474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612001474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:27:42Z","timestamp":1758418062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619612001474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0025619612001474"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.09.009","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline Predictors of Androgen Deprivation Therapy Response in Advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}